✉  info@marketresearchfuture.com   📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Vasomotor Symptoms Market Research Report Information By Therapy Type (Hormonal, Non-Hormonal), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Stores), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) – Market Forecast Till 2032


ID: MRFR/HC/8332-HCR | 153 Pages | Author: Rahul Gotadki| November 2024

 


Vasomotor Symptoms Market Segmentation


Vasomotor Symptoms Treatment Therapy Type Outlook (USD Billion, 2019-2030)




  • Hormonal




  • Non-Hormonal




Vasomotor Symptoms Distribution Channel Outlook (USD Billion, 2019-2030)




  • Hospital Pharmacies




  • Retail Pharmacies




  • Online Stores




Vasomotor Symptoms Regional Outlook (USD Billion, 2019-2030)




  • North America Outlook (USD Billion, 2019-2030)




    • North America Vasomotor Symptoms by Treatment Therapy Type




      • Hormonal




      • Non-Hormonal






    • North America Vasomotor Symptoms by Distribution Channel




      • Hospital Pharmacies




      • Retail Pharmacies




      • Online Stores






    • US Outlook (USD Billion, 2019-2030)




    • US Vasomotor Symptoms by Treatment Therapy Type




      • Hormonal




      • Non-Hormonal






    • US Vasomotor Symptoms by Distribution Channel




      • Hospital Pharmacies




      • Retail Pharmacies




      • Online Stores






    • CANADA Outlook (USD Billion, 2019-2030)




    • CANADA Vasomotor Symptoms by Treatment Therapy Type




      • Hormonal




      • Non-Hormonal






    • CANADA Vasomotor Symptoms by Distribution Channel




      • Hospital Pharmacies




      • Retail Pharmacies




      • Online Stores








  • Europe Outlook (USD Billion, 2019-2030)




    • Europe Vasomotor Symptoms by Treatment Therapy Type




      • Hormonal




      • Non-Hormonal






    • Europe Vasomotor Symptoms by Distribution Channel




      • Hospital Pharmacies




      • Retail Pharmacies




      • Online Stores






    • Germany Outlook (USD Billion, 2019-2030)




    • Germany Vasomotor Symptoms by Treatment Therapy Type




      • Hormonal




      • Non-Hormonal






    • Germany Vasomotor Symptoms by Distribution Channel




      • Hospital Pharmacies




      • Retail Pharmacies




      • Online Stores






    • France Outlook (USD Billion, 2019-2030)




    • France Vasomotor Symptoms by Treatment Therapy Type




      • Hormonal




      • Non-Hormonal






    • France Vasomotor Symptoms by Distribution Channel




      • Hospital Pharmacies




      • Retail Pharmacies




      • Online Stores






    • UK Outlook (USD Billion, 2019-2030)




    • UK Vasomotor Symptoms by Treatment Therapy Type




      • Hormonal




      • Non-Hormonal






    • UK Vasomotor Symptoms by Distribution Channel




      • Hospital Pharmacies




      • Retail Pharmacies




      • Online Stores






    • ITALY Outlook (USD Billion, 2019-2030)




    • ITALY Vasomotor Symptoms by Treatment Therapy Type




      • Hormonal




      • Non-Hormonal






    • ITALY Vasomotor Symptoms by Distribution Channel




      • Hospital Pharmacies




      • Retail Pharmacies




      • Online Stores






    • SPAIN Outlook (USD Billion, 2019-2030)




    • SPAIN Vasomotor Symptoms by Treatment Therapy Type




      • Hormonal




      • Non-Hormonal






    • SPAIN Vasomotor Symptoms by Distribution Channel




      • Hospital Pharmacies




      • Retail Pharmacies




      • Online Stores






    • Rest Of Europe Outlook (USD Billion, 2019-2030)




    • Rest Of Europe Vasomotor Symptoms by Treatment Therapy Type




      • Hormonal




      • Non-Hormonal






    • Rest Of Europe Vasomotor Symptoms by Distribution Channel




      • Hospital Pharmacies




      • Retail Pharmacies




      • Online Stores








  • Asia-Pacific Outlook (USD Billion, 2019-2030)




    • Asia-Pacific Vasomotor Symptoms by Treatment Therapy Type




      • Hormonal




      • Non-Hormonal






    • Asia-Pacific Vasomotor Symptoms by Distribution Channel




      • Hospital Pharmacies




      • Retail Pharmacies




      • Online Stores






    • China Outlook (USD Billion, 2019-2030)




    • China Vasomotor Symptoms by Treatment Therapy Type




      • Hormonal




      • Non-Hormonal






    • China Vasomotor Symptoms by Distribution Channel




      • Hospital Pharmacies




      • Retail Pharmacies




      • Online Stores






    • Japan Outlook (USD Billion, 2019-2030)




    • Japan Vasomotor Symptoms by Treatment Therapy Type




      • Hormonal




      • Non-Hormonal






    • Japan Vasomotor Symptoms by Distribution Channel




      • Hospital Pharmacies




      • Retail Pharmacies




      • Online Stores






    • India Outlook (USD Billion, 2019-2030)




    • India Vasomotor Symptoms by Treatment Therapy Type




      • Hormonal




      • Non-Hormonal






    • India Vasomotor Symptoms by Distribution Channel




      • Hospital Pharmacies




      • Retail Pharmacies




      • Online Stores






    • Australia Outlook (USD Billion, 2019-2030)




    • Australia Vasomotor Symptoms by Treatment Therapy Type




      • Hormonal




      • Non-Hormonal






    • Australia Vasomotor Symptoms by Distribution Channel




      • Hospital Pharmacies




      • Retail Pharmacies




      • Online Stores






    • Rest of Asia-Pacific Outlook (USD Billion, 2019-2030)




    • Rest of Asia-Pacific Vasomotor Symptoms by Treatment Therapy Type




      • Hormonal




      • Non-Hormonal






    • Rest of Asia-Pacific Vasomotor Symptoms by Distribution Channel




      • Hospital Pharmacies




      • Retail Pharmacies




      • Online Stores








  • Rest of the World Outlook (USD Billion, 2019-2030)




    • Rest of the World Vasomotor Symptoms by Treatment Therapy Type




      • Hormonal




      • Non-Hormonal






    • Rest of the World Vasomotor Symptoms by Distribution Channel




      • Hospital Pharmacies




      • Retail Pharmacies




      • Online Stores






    • Middle East Outlook (USD Billion, 2019-2030)




    • Middle East Vasomotor Symptoms by Treatment Therapy Type




      • Hormonal




      • Non-Hormonal






    • Middle East Vasomotor Symptoms by Distribution Channel




      • Hospital Pharmacies




      • Retail Pharmacies




      • Online Stores






    • Africa Outlook (USD Billion, 2019-2030)




    • Africa Vasomotor Symptoms by Treatment Therapy Type




      • Hormonal




      • Non-Hormonal






    • Africa Vasomotor Symptoms by Distribution Channel




      • Hospital Pharmacies




      • Retail Pharmacies




      • Online Stores






    • Latin America Outlook (USD Billion, 2019-2030)




    • Latin America Vasomotor Symptoms by Treatment Therapy Type




      • Hormonal




      • Non-Hormonal






    • Latin America Vasomotor Symptoms by Distribution Channel




      • Hospital Pharmacies




      • Retail Pharmacies




      • Online Stores










Research Methodology on Vasomotor Symptoms Market


In order to conduct a comprehensive evaluation of the Vasomotor Symptoms market, Market Research Future (MRFR) employed a research approach based on the PESTEL (political, economic, social, technological, environmental, and legal) model. This approach is meant to provide an objective basis for analysing the Vasomotor Symptoms market.


The research is undertaken using both primary and secondary data sources. Primary data is collected through extensive desk research and interviews with industry experts, while secondary data is obtained from both industry and government sources. The primary sources of data used in the study include industry journals, company websites, and annual reports. Government sources included World Bank, National Health Service (UK), and Office for National Statistics (UK).


For in-depth analysis, MRFR utilized tools such as Porter’s Five Forces, market attractiveness index, PESTEL framework and value chain analysis to identify market dynamics, key trends and the competitive outlook of the Vasomotor Symptoms market. Moreover, in order to add an understanding of the drivers and challenges of the market, MRFR conducted surveys and expert interviews with key stakeholders in the market.


MRFR further developed a statistical model of the Vasomotor Symptoms market and made use of linear and logistic regression. Regression analysis is used to determine the correlation between the factors affecting the market and their potential impact on market growth. The data obtained is normalised using a weighted average to arrive at the most indicative estimates.


Finally, MRFR conducted a market scenario and sensitivity analysis to identify the best course of action when facing a variety of price and supply scenarios in the market. The overall assessment of the Vasomotor Symptoms market is conducted using descriptive, explanatory, predictive and intelligence analysis methods. Descriptive analysis is used to describe the factors impacting the market and predictive analytics is used to forecast the outcome from 2023 to 2030.


The report is designed to provide an in-depth assessment of the Vasomotor Symptoms market, with a focus on the following key components:



  • Market overview and structure

  • Market dynamics

  • Major market players and their strategies

  • Market segmentation by key product types

  • Regional analyses and forecast

  • Regulatory landscape and trade analysis

  • SWOT analysis

  • Porter’s Five Forces analysis

  • Market attractiveness index

  • Market size and forecast

  • Key trends and innovations

  • Risk factors

  • Value chain analysis

  • Key success factors


In order to validate the derived market figures, MRFR conducted multiple market simulations, using a set of assumptions based on market survey results, interviews with leading market players, and secondary sources such as company websites, reports, and publications. The simulations conducted yielded the market estimates for the Vasomotor Symptoms market. This, in combination with primary and secondary research, enabled the team to fine-tune the accuracy of the established figures.

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Please fill in Business Email for Quick Response

Table of Contents

1. EXECUTIVE SUMMARY

1.1. Market Attractiveness Analysis

1.1.1. Global Vasomotor Symptoms Market, by Therapy Type

1.1.2. Global Vasomotor Symptoms Market, by Distribution Channel

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.3. Research Objective

2.4. List of Assumptions & Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Data Mining

3.3. Secondary Research

3.4. Primary Research

3.4.1. Breakdown of Primary Respondents

3.5. Forecasting Techniques

3.6. Research Methodology for Market Size Estimation

3.6.1. Bottom-Up Approach

3.6.2. Top-Down Approach

3.7. Data Triangulation

3.8. Validation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis

5.2.1. R&D and Designing

5.2.2. Manufacturing

5.2.3. Distribution and Sales

5.2.4. Post Sales Services

5.3. Impact of COVID-19 on Vasomotor Symptoms Market

5.3.1. Impact on R&D

5.3.2. Impact on Production

5.3.3. Impact on Regions

6. GLOBAL VASOMOTOR SYMPTOMS MARKET, BY THERAPY TYPE

6.1. Overview

6.2. Hormonal

6.2.1. Estrogen

Market Estimates & Forecast, by Region, 2023-2030

Market Estimates & Forecast, by Country, 2023-2030

6.2.2. Progesterone

Market Estimates & Forecast, by Region, 2023-2030

Market Estimates & Forecast, by Country, 2023-2030

6.2.3. Combination

Market Estimates & Forecast, by Region, 2023-2030

Market Estimates & Forecast, by Country, 2023-2030

6.3. Non¬-Hormonal

6.3.1. Anti-Depressants

Market Estimates & Forecast, by Region, 2023-2030

Market Estimates & Forecast, by Country, 2023-2030

6.3.2. Others

Market Estimates & Forecast, by Region, 2023-2030

Market Estimates & Forecast, by Country, 2023-2030

7. GLOBAL VASOMOTOR SYMPTOMS MARKET, BY DISTRIBUTION CHANNEL

7.1. Overview

7.2. Hospital Pharmacies

Market Estimates & Forecast, by Region, 2023-2030

Market Estimates & Forecast, by Country, 2023-2030

7.3. Retail Pharmacies

Market Estimates & Forecast, by Region, 2023-2030

Market Estimates & Forecast, by Country, 2023-2030

7.4. Online Stores

Market Estimates & Forecast, by Region, 2023-2030

Market Estimates & Forecast, by Country, 2023-2030

8. GLOBAL VASOMOTOR SYMPTOMS MARKET, BY REGION

8.1. Overview

8.2. Americas

8.2.1. North America

8.2.1.1. US

8.2.1.2. Canada

8.2.2. Latin America

8.3. Europe

8.3.1. Western Europe

8.3.1.1. Germany

8.3.1.2. France

8.3.1.3. UK

8.3.1.4. Italy

8.3.1.5. Spain

8.3.1.6. Rest of Western Europe

8.3.2. Eastern Europe

8.4. Asia-Pacific

8.4.1. Japan

8.4.2. China

8.4.3. India

8.4.4. Australia

8.4.5. South Korea

8.4.6. Rest of Asia-Pacific

8.5. Middle East & Africa

8.5.1. Middle East

8.5.2. Africa

9. COMPANY LANDSCAPE

9.1. Overview

9.2. Competitive Analysis

9.3. Company Share Analysis

9.4. Competitor Dashboard

9.5. Major Growth Strategy in the Global Vasomotor Symptoms Market

9.6. Competitive Benchmarking

9.7. Leading Player in terms of Number of Developments in the Global Vasomotor Symptoms Market

9.8. Key Developments & Growth Strategies

9.8.1. New Product Launch

9.8.2. Merger & Acquisition

9.8.3. Joint Ventures

9.9. Major Players Financial Matrix & Market Ratio

9.9.1. Sales & Operating Income 2019

9.9.2. Major Players R&D Expenditure 2019

10. COMPANY PROFILES

10.1. Allergan

10.1.1. Company Overview

10.1.2. Products/Services Offered

10.1.3. Financial Overview

10.1.4. Key Developments

10.1.5. SWOT Analysis

10.1.6. Key Strategies

10.2. Eli Lily and Company

10.3. Amag Pharmaceuticals

10.4. EndoCeutics, Inc.

10.5. Emcure Pharmaceuticals Ltd

10.6. Merck & Co., Inc.

10.7. Mithra Pharmaceuticals

10.8. Novartis AG

10.9. Novo Nordisk A/S

10.10. Pfizer Inc.

10.11. Procter & Gamble

10.12. Teva Pharmaceuticals

10.13. TherapeuticsMD, Inc.

10.14. Others

11. APPENDIX

11.1. References

11.2. Related Reports

LIST OF TABLES

TABLE 1 GLOBAL VASOMOTOR SYMPTOMS MARKET SYNOPSIS, 2023-2030

TABLE 2 GLOBAL VASOMOTOR SYMPTOMS MARKET ESTIMATES & FORECAST, 2023-2030 (USD MILLION)

TABLE 3 GLOBAL VASOMOTOR SYMPTOMS MARKET, BY THERAPY TYPE, 2023-2030 (USD MILLION)

TABLE 4 GLOBAL VASOMOTOR SYMPTOMS MARKET, FOR HORMONAL, BY TYPE, 2023-2030 (USD MILLION)

TABLE 5 GLOBAL VASOMOTOR SYMPTOMS MARKET, FOR NON-HORMONAL, BY TYPE, 2023-2030 (USD MILLION)

TABLE 6 GLOBAL VASOMOTOR SYMPTOMS MARKET, BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

TABLE 7 GLOBAL VASOMOTOR SYMPTOMS MARKET, BY REGION, 2023-2030 (USD MILLION)

TABLE 8 AMERICAS: VASOMOTOR SYMPTOMS MARKET, BY THERAPY TYPE, 2023-2030 (USD MILLION)

TABLE 9 AMERICAS: VASOMOTOR SYMPTOMS MARKET, FOR HORMONAL, BY TYPE, 2023-2030 (USD MILLION)

TABLE 10 AMERICAS: VASOMOTOR SYMPTOMS MARKET, FOR NON-HORMONAL, BY TYPE, 2023-2030 (USD MILLION)

TABLE 11 AMERICAS: VASOMOTOR SYMPTOMS MARKET, BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

TABLE 12 NORTH AMERICA: VASOMOTOR SYMPTOMS MARKET, BY THERAPY TYPE, 2023-2030 (USD MILLION)

TABLE 13 NORTH AMERICA: VASOMOTOR SYMPTOMS MARKET, FOR HORMONAL, BY TYPE, 2023-2030 (USD MILLION)

TABLE 14 NORTH AMERICA: VASOMOTOR SYMPTOMS MARKET, FOR NON-HORMONAL, BY TYPE, 2023-2030 (USD MILLION)

TABLE 15 NORTH AMERICA: VASOMOTOR SYMPTOMS MARKET, BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

TABLE 16 US: VASOMOTOR SYMPTOMS MARKET, BY THERAPY TYPE, 2023-2030 (USD MILLION)

TABLE 17 US: VASOMOTOR SYMPTOMS MARKET, FOR HORMONAL, BY TYPE, 2023-2030 (USD MILLION)

TABLE 18 US: VASOMOTOR SYMPTOMS MARKET, FOR NON-HORMONAL, BY TYPE, 2023-2030 (USD MILLION)

TABLE 19 US: VASOMOTOR SYMPTOMS MARKET, BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

TABLE 20 CANADA: VASOMOTOR SYMPTOMS MARKET, BY THERAPY TYPE, 2023-2030 (USD MILLION)

TABLE 21 CANADA: VASOMOTOR SYMPTOMS MARKET, FOR HORMONAL, BY TYPE, 2023-2030 (USD MILLION)

TABLE 22 CANADA: VASOMOTOR SYMPTOMS MARKET, FOR NON-HORMONAL, BY TYPE, 2023-2030 (USD MILLION)

TABLE 23 CANADA: VASOMOTOR SYMPTOMS MARKET, BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

TABLE 24 LATIN AMERICA: VASOMOTOR SYMPTOMS MARKET, BY THERAPY TYPE, 2023-2030 (USD MILLION)

TABLE 25 LATIN AMERICA: VASOMOTOR SYMPTOMS MARKET, FOR HORMONAL, BY TYPE, 2023-2030 (USD MILLION)

TABLE 26 LATIN AMERICA: VASOMOTOR SYMPTOMS MARKET, FOR NON-HORMONAL, BY TYPE, 2023-2030 (USD MILLION)

TABLE 27 LATIN AMERICA: VASOMOTOR SYMPTOMS MARKET, BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

TABLE 28 EUROPE: VASOMOTOR SYMPTOMS MARKET, BY THERAPY TYPE, 2023-2030 (USD MILLION)

TABLE 29 EUROPE: VASOMOTOR SYMPTOMS MARKET, FOR HORMONAL, BY TYPE, 2023-2030 (USD MILLION)

TABLE 30 EUROPE: VASOMOTOR SYMPTOMS MARKET, FOR NON-HORMONAL, BY TYPE, 2023-2030 (USD MILLION)

TABLE 31 EUROPE: VASOMOTOR SYMPTOMS MARKET, BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

TABLE 32 WESTERN EUROPE: VASOMOTOR SYMPTOMS MARKET, BY THERAPY TYPE, 2023-2030 (USD MILLION)

TABLE 33 WESTERN EUROPE: VASOMOTOR SYMPTOMS MARKET, FOR HORMONAL, BY TYPE, 2023-2030 (USD MILLION)

TABLE 34 WESTERN EUROPE: VASOMOTOR SYMPTOMS MARKET, FOR NON-HORMONAL, BY TYPE, 2023-2030 (USD MILLION)

TABLE 35 WESTERN EUROPE: VASOMOTOR SYMPTOMS MARKET, BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

TABLE 36 GERMANY: VASOMOTOR SYMPTOMS MARKET, BY THERAPY TYPE, 2023-2030 (USD MILLION)

TABLE 37 GERMANY: VASOMOTOR SYMPTOMS MARKET, FOR HORMONAL, BY TYPE, 2023-2030 (USD MILLION)

TABLE 38 GERMANY: VASOMOTOR SYMPTOMS MARKET, FOR NON-HORMONAL, BY TYPE, 2023-2030 (USD MILLION)

TABLE 39 GERMANY: VASOMOTOR SYMPTOMS MARKET, BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

TABLE 40 FRANCE: VASOMOTOR SYMPTOMS MARKET, BY THERAPY TYPE, 2023-2030 (USD MILLION)

TABLE 41 FRANCE: VASOMOTOR SYMPTOMS MARKET, FOR HORMONAL, BY TYPE, 2023-2030 (USD MILLION)

TABLE 42 FRANCE: VASOMOTOR SYMPTOMS MARKET, FOR NON-HORMONAL, BY TYPE, 2023-2030 (USD MILLION)

TABLE 43 FRANCE: VASOMOTOR SYMPTOMS MARKET, BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

TABLE 44 UK: VASOMOTOR SYMPTOMS MARKET, BY THERAPY TYPE, 2023-2030 (USD MILLION)

TABLE 45 UK: VASOMOTOR SYMPTOMS MARKET, FOR HORMONAL, BY TYPE, 2023-2030 (USD MILLION)

TABLE 46 UK: VASOMOTOR SYMPTOMS MARKET, FOR NON-HORMONAL, BY TYPE, 2023-2030 (USD MILLION)

TABLE 47 UK: VASOMOTOR SYMPTOMS MARKET, BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

TABLE 48 ITALY: VASOMOTOR SYMPTOMS MARKET, BY THERAPY TYPE, 2023-2030 (USD MILLION)

TABLE 49 ITALY: VASOMOTOR SYMPTOMS MARKET, FOR HORMONAL, BY TYPE, 2023-2030 (USD MILLION)

TABLE 50 ITALY: VASOMOTOR SYMPTOMS MARKET, FOR NON-HORMONAL, BY TYPE, 2023-2030 (USD MILLION)

TABLE 51 ITALY: VASOMOTOR SYMPTOMS MARKET, BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

TABLE 52 SPAIN: VASOMOTOR SYMPTOMS MARKET, BY THERAPY TYPE, 2023-2030 (USD MILLION)

TABLE 53 SPAIN: VASOMOTOR SYMPTOMS MARKET, FOR HORMONAL, BY TYPE, 2023-2030 (USD MILLION)

TABLE 54 SPAIN: VASOMOTOR SYMPTOMS MARKET, FOR NON-HORMONAL, BY TYPE, 2023-2030 (USD MILLION)

TABLE 55 SPAIN: VASOMOTOR SYMPTOMS MARKET, BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

TABLE 56 REST OF WESTERN EUROPE: VASOMOTOR SYMPTOMS MARKET, BY THERAPY TYPE, 2023-2030 (USD MILLION)

TABLE 57 REST OF WESTERN EUROPE: VASOMOTOR SYMPTOMS MARKET, FOR HORMONAL, BY TYPE, 2023-2030 (USD MILLION)

TABLE 58 REST OF WESTERN EUROPE: VASOMOTOR SYMPTOMS MARKET, FOR NON-HORMONAL, BY TYPE, 2023-2030 (USD MILLION)

TABLE 59 REST OF WESTERN EUROPE: VASOMOTOR SYMPTOMS MARKET, BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

TABLE 60 EASTERN EUROPE: VASOMOTOR SYMPTOMS MARKET, BY THERAPY TYPE, 2023-2030 (USD MILLION)

TABLE 61 EASTERN EUROPE: VASOMOTOR SYMPTOMS MARKET, FOR HORMONAL, BY TYPE, 2023-2030 (USD MILLION)

TABLE 62 EASTERN EUROPE: VASOMOTOR SYMPTOMS MARKET, FOR NON-HORMONAL, BY TYPE, 2023-2030 (USD MILLION)

TABLE 63 EASTERN EUROPE: VASOMOTOR SYMPTOMS MARKET, BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

TABLE 64 ASIA-PACIFIC: VASOMOTOR SYMPTOMS MARKET, BY THERAPY TYPE, 2023-2030 (USD MILLION)

TABLE 65 ASIA-PACIFIC: VASOMOTOR SYMPTOMS MARKET, FOR HORMONAL, BY TYPE, 2023-2030 (USD MILLION)

TABLE 66 ASIA-PACIFIC: VASOMOTOR SYMPTOMS MARKET, FOR NON-HORMONAL, BY TYPE, 2023-2030 (USD MILLION)

TABLE 67 ASIA-PACIFIC: VASOMOTOR SYMPTOMS MARKET, BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

TABLE 68 JAPAN: VASOMOTOR SYMPTOMS MARKET, BY THERAPY TYPE, 2023-2030 (USD MILLION)

TABLE 69 JAPAN: VASOMOTOR SYMPTOMS MARKET, FOR HORMONAL, BY TYPE, 2023-2030 (USD MILLION)

TABLE 70 JAPAN: VASOMOTOR SYMPTOMS MARKET, FOR NON-HORMONAL, BY TYPE, 2023-2030 (USD MILLION)

TABLE 71 JAPAN: VASOMOTOR SYMPTOMS MARKET, BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

TABLE 72 CHINA: VASOMOTOR SYMPTOMS MARKET, BY THERAPY TYPE, 2023-2030 (USD MILLION)

TABLE 73 CHINA: VASOMOTOR SYMPTOMS MARKET, FOR HORMONAL, BY TYPE, 2023-2030 (USD MILLION)

TABLE 74 CHINA: VASOMOTOR SYMPTOMS MARKET, FOR NON-HORMONAL, BY TYPE, 2023-2030 (USD MILLION)

TABLE 75 CHINA: VASOMOTOR SYMPTOMS MARKET, BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

TABLE 76 INDIA: VASOMOTOR SYMPTOMS MARKET, BY THERAPY TYPE, 2023-2030 (USD MILLION)

TABLE 77 INDIA: VASOMOTOR SYMPTOMS MARKET, FOR HORMONAL, BY TYPE, 2023-2030 (USD MILLION)

TABLE 78 INDIA: VASOMOTOR SYMPTOMS MARKET, FOR NON-HORMONAL, BY TYPE, 2023-2030 (USD MILLION)

TABLE 79 INDIA: VASOMOTOR SYMPTOMS MARKET, BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

TABLE 80 AUSTRALIA: VASOMOTOR SYMPTOMS MARKET, BY THERAPY TYPE, 2023-2030 (USD MILLION)

TABLE 81 AUSTRALIA: VASOMOTOR SYMPTOMS MARKET, FOR HORMONAL, BY TYPE, 2023-2030 (USD MILLION)

TABLE 82 AUSTRALIA: VASOMOTOR SYMPTOMS MARKET, FOR NON-HORMONAL, BY TYPE, 2023-2030 (USD MILLION)

TABLE 83 AUSTRALIA: VASOMOTOR SYMPTOMS MARKET, BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

TABLE 84 SOUTH KOREA: VASOMOTOR SYMPTOMS MARKET, BY THERAPY TYPE, 2023-2030 (USD MILLION)

TABLE 85 SOUTH KOREA: VASOMOTOR SYMPTOMS MARKET, FOR HORMONAL, BY TYPE, 2023-2030 (USD MILLION)

TABLE 86 SOUTH KOREA: VASOMOTOR SYMPTOMS MARKET, FOR NON-HORMONAL, BY TYPE, 2023-2030 (USD MILLION)

TABLE 87 SOUTH KOREA: VASOMOTOR SYMPTOMS MARKET, BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

TABLE 88 REST OF ASIA-PACIFIC: VASOMOTOR SYMPTOMS MARKET, BY THERAPY TYPE, 2023-2030 (USD MILLION)

TABLE 89 REST OF ASIA-PACIFIC: VASOMOTOR SYMPTOMS MARKET, FOR HORMONAL, BY TYPE, 2023-2030 (USD MILLION)

TABLE 90 REST OF ASIA-PACIFIC: VASOMOTOR SYMPTOMS MARKET, FOR NON-HORMONAL, BY TYPE, 2023-2030 (USD MILLION)

TABLE 91 REST OF ASIA-PACIFIC: VASOMOTOR SYMPTOMS MARKET, BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

TABLE 92 MIDDLE EAST & AFRICA: VASOMOTOR SYMPTOMS MARKET, BY THERAPY TYPE, 2023-2030 (USD MILLION)

TABLE 93 MIDDLE EAST & AFRICA: VASOMOTOR SYMPTOMS MARKET, FOR HORMONAL, BY TYPE, 2023-2030 (USD MILLION)

TABLE 94 MIDDLE EAST & AFRICA: VASOMOTOR SYMPTOMS MARKET, FOR NON-HORMONAL, BY TYPE, 2023-2030 (USD MILLION)

TABLE 95 MIDDLE EAST & AFRICA: VASOMOTOR SYMPTOMS MARKET, BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

TABLE 96 MIDDLE EAST: VASOMOTOR SYMPTOMS MARKET, BY THERAPY TYPE, 2023-2030 (USD MILLION)

TABLE 97 MIDDLE EAST: VASOMOTOR SYMPTOMS MARKET, FOR HORMONAL, BY TYPE, 2023-2030 (USD MILLION)

TABLE 98 MIDDLE EAST: VASOMOTOR SYMPTOMS MARKET, FOR NON-HORMONAL, BY TYPE, 2023-2030 (USD MILLION)

TABLE 99 MIDDLE EAST: VASOMOTOR SYMPTOMS MARKET, BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

TABLE 100 AFRICA: VASOMOTOR SYMPTOMS MARKET, BY THERAPY TYPE, 2023-2030 (USD MILLION)

TABLE 101 AFRICA: VASOMOTOR SYMPTOMS MARKET, FOR HORMONAL, BY TYPE, 2023-2030 (USD MILLION)

TABLE 102 AFRICA: VASOMOTOR SYMPTOMS MARKET, FOR NON-HORMONAL, BY TYPE, 2023-2030 (USD MILLION)

TABLE 103 AFRICA: VASOMOTOR SYMPTOMS MARKET, BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL VASOMOTOR SYMPTOMS MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL VASOMOTOR SYMPTOMS MARKET

FIGURE 4 GLOBAL VASOMOTOR SYMPTOMS MARKET SHARE, BY THERAPY TYPE, 2019 (%)

FIGURE 5 GLOBAL VASOMOTOR SYMPTOMS MARKET SHARE, BY DISTRIBUTION CHANNEL, 2019 (%)

FIGURE 6 GLOBAL VASOMOTOR SYMPTOMS MARKET SHARE, BY REGION, 2019 (%)

FIGURE 7 AMERICAS: VASOMOTOR SYMPTOMS MARKET SHARE BY REGION, 2019 (%)

FIGURE 8 NORTH AMERICA: VASOMOTOR SYMPTOMS MARKET SHARE, BY COUNTRY, 2019 (%)

FIGURE 9 EUROPE: VASOMOTOR SYMPTOMS MARKET SHARE, BY REGION, 2019 (%)

FIGURE 10 WESTERN EUROPE: VASOMOTOR SYMPTOMS MARKET SHARE, BY COUNTRY, 2019 (%)

FIGURE 11 ASIA-PACIFIC: VASOMOTOR SYMPTOMS MARKET SHARE, BY COUNTRY, 2019 (%)

FIGURE 12 MIDDLE EAST & AFRICA: VASOMOTOR SYMPTOMS MARKET SHARE, BY REGION, 2019 (%)

FIGURE 13 GLOBAL VASOMOTOR SYMPTOMS MARKET: COMPANY SHARE ANALYSIS, 2019 (%)

FIGURE 14 ALLERGAN: KEY FINANCIALS

FIGURE 15 ALLERGAN: SEGMENTAL REVENUE

FIGURE 16 ALLERGAN: REGIONAL REVENUE

FIGURE 17 ELI LILY AND COMPANY: KEY FINANCIALS

FIGURE 18 ELI LILY AND COMPANY: SEGMENTAL REVENUE

FIGURE 19 ELI LILY AND COMPANY: REGIONAL REVENUE

FIGURE 20 AMAG PHARMACEUTICALS: KEY FINANCIALS

FIGURE 21 AMAG PHARMACEUTICALS: SEGMENTAL REVENUE

FIGURE 22 AMAG PHARMACEUTICALS: REGIONAL REVENUE

FIGURE 23 EMCURE PHARMACEUTICALS LTD: KEY FINANCIALS

FIGURE 24 EMCURE PHARMACEUTICALS LTD: SEGMENTAL REVENUE

FIGURE 25 EMCURE PHARMACEUTICALS LTD: REGIONAL REVENUE

FIGURE 26 ENDOCEUTICS, INC.: KEY FINANCIALS

FIGURE 27 ENDOCEUTICS, INC.: SEGMENTAL REVENUE

FIGURE 28 ENDOCEUTICS, INC.: REGIONAL REVENUE

FIGURE 29 MERCK & CO., INC.: KEY FINANCIALS

FIGURE 30 MERCK & CO., INC.: SEGMENTAL REVENUE

FIGURE 31 MERCK & CO., INC.: REGIONAL REVENUE

FIGURE 32 MITHRA PHARMACEUTICALS: KEY FINANCIALS

FIGURE 33 MITHRA PHARMACEUTICALS: SEGMENTAL REVENUE

FIGURE 34 MITHRA PHARMACEUTICALS: REGIONAL REVENUE

FIGURE 35 NOVARTIS AG: KEY FINANCIALS

FIGURE 36 NOVARTIS AG: SEGMENTAL REVENUE

FIGURE 37 NOVARTIS AG: REGIONAL REVENUE

FIGURE 38 NOVO NORDISK A/S: KEY FINANCIALS

FIGURE 39 NOVO NORDISK A/S: SEGMENTAL REVENUE

FIGURE 40 NOVO NORDISK A/S: REGIONAL REVENUE

FIGURE 41 PFIZER INC.: KEY FINANCIALS

FIGURE 42 PFIZER INC.: SEGMENTAL REVENUE

FIGURE 43 PFIZER INC.: REGIONAL REVENUE

FIGURE 44 PROCTER & GAMBLE: KEY FINANCIALS

FIGURE 45 PROCTER & GAMBLE: SEGMENTAL REVENUE

FIGURE 46 PROCTER & GAMBLE: REGIONAL REVENUE

FIGURE 47 TEVA PHARMACEUTICALS: KEY FINANCIALS

FIGURE 48 TEVA PHARMACEUTICALS: SEGMENTAL REVENUE

FIGURE 49 TEVA PHARMACEUTICALS: REGIONAL REVENUE

FIGURE 50 THERAPEUTICSMD, INC.: KEY FINANCIALS

FIGURE 51 THERAPEUTICSMD, INC.: SEGMENTAL REVENUE

FIGURE 52 THERAPEUTICSMD, INC.: REGIONAL REVENUE

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.
Press Release
Category icon
Vasomotor Symptoms Market: Increasing Product Launches, Coupled with the rise in Clinical Trial D...
Logo
Dmca Cloudflare ssl
Paypal footer Ssl
Services Industry Expertise Consulting Services Articles How To Order FAQs
Our Company About US Careers Contact Us Terms & Conditions Privacy Policy
Banking Partners
Amex Mastercard1
Razerpay
Hdfcbank
Visa
✉  info@marketresearchfuture.com
📞  +1 (855) 661-4441(US)
📞  +44 1720 412 167(UK)

© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)